Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

React to this article
Latest news
Date Title
04:11a DIRECTCASH PAYMENTS : DC Payments, BMO sign ATM deal covering Shell Canada locations
04:11a Analysis - If Greece falls, no one wants their prints on the murder weapon
04:11aDJNepal Earthquake Brings Everest Avalanche -- 2nd Update
04:08a If Greece falls, no one wants their prints on the murder weapon
03:53a ASIANA AIRLINES : plane moved nearly 2 weeks after botched landing
03:50a NATIONAL BANK OF ABU DHABI : NBAD participates in National Career Exhibition in Dubai
03:50a NORTHROP GRUMMAN : Fujairah Gladiators win top prize in UAE Innovation Challenge 2015
03:47a GO : to invest over €50 million to launch 'internet of the future'
03:45a STRAUMANN : UPDATE – Straumann: Invitation – 2015 First-quarter sales report – Conference call and audio webcast
03:37a HSBC : SACO's IPO covered 191% in 3rd day
Latest news
Advertisement
Hot News 
GCP STUDENT LIVING : Dividend Declaration and Net Asset Valuation
AERIE PHARMACEUTICALS : Pharma plunges aftermarket as Rhopressa study fails
SYQIC : Gets Working Capital Facility Offer, Improves Cash Position
INNATE PHARMA : and AstraZeneca announce global agreement for IPH2201 in immuno-oncology
French Connection warns on full-year results
Most Read News
04/25 DEUTSCHE BANK : to keep 500 German retail branches - Welt am Sonntag
04/25 KROGER : accounting celebrates 20 years of growth in Hutchinson
04/25 MANCHESTER UNITED : Rooney, Abramovich, Branson in UK Rich List
04/25 SOLARCITY : Town of Plattsburgh exploring solar project
04/25 MICROSOFT : Forty Years and a Big Slip
Most recommended articles
04:11a Analysis - If Greece falls, no one wants their prints on the murder weapon
04:11aDJNepal Earthquake Brings Everest Avalanche -- 2nd Update
04:08a If Greece falls, no one wants their prints on the murder weapon
02:22aDJVolkswagen Chairman Piech Resigns -- 2nd Update
12:23a Cuts to pay and perks trigger flight from China's state banks
Dynamic quotes  
ON
| OFF